BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 22739665)

  • 1. Haemoperitoneum as an indicator of GIST.
    de Juan Ferré A; Gutiérrez L; Garicano F; Malaxetxebarria S; Fernández F
    Anticancer Drugs; 2012 Jun; 23 Suppl():S10-2. PubMed ID: 22739665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient with high-risk GIST not associated with c-KIT mutations: same benefit from adjuvant therapy?
    Izquierdo ME; Bonastre MT
    Anticancer Drugs; 2012 Jun; 23 Suppl():S7-9. PubMed ID: 22739668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CT scan is not everything in the evaluation of a patient with gastrointestinal tumors (GIST) under imatinib therapy.
    Wang CM; Fu H; Zhao GF; Wang J; Shi YQ
    Pathol Oncol Res; 2012 Oct; 18(4):1095-7. PubMed ID: 21927980
    [No Abstract]   [Full Text] [Related]  

  • 4. Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection.
    Tirumani SH; Shinagare AB; Jagannathan JP; Krajewski KM; Ramaiya NH; Raut CP
    Eur J Surg Oncol; 2014 Apr; 40(4):420-8. PubMed ID: 24238762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congestive heart failure in a 77-year-old woman receiving adjuvant treatment with imatinib for a large gastric gastrointestinal stromal tumour.
    Pulido EG; Riquelme A; Ballesteros J; Vaz MÁ
    Anticancer Drugs; 2012 Jun; 23 Suppl():S15-7. PubMed ID: 22739666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy.
    Pandey R; Kochar R
    J Gastrointest Cancer; 2012 Dec; 43(4):547-52. PubMed ID: 22847491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor rupture exposes the patient to an increased risk of relapse, regardless of the size and number of mitoses.
    Quintero CB; Cubedo R
    Anticancer Drugs; 2012 Jun; 23 Suppl():S1-2. PubMed ID: 22739664
    [No Abstract]   [Full Text] [Related]  

  • 8. [Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
    Shen L
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):438-9. PubMed ID: 17845753
    [No Abstract]   [Full Text] [Related]  

  • 9. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
    JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
    Valls-Ferrusola E; García-Garzón JR; Ponce-López A; Soler-Peter M; Fuertes-Cabero S; Moragas-Solanes M; Riera-Gil E; Carrió-Gasset I; Lomeña-Caballero F
    Rev Esp Enferm Dig; 2012 Jul; 104(7):360-6. PubMed ID: 22849497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
    Zheng S; Jia J; Pan YL; Tao DY; Lu HS
    Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment with sunitinib in a young patient with metastatic gastrointestinal stromal tumor after failure on adjuvant imatinib.
    Kapoor R; Khosla D; Kumar P; Kumar N; Bera A
    J Cancer Res Ther; 2011; 7(4):491-3. PubMed ID: 22269418
    [No Abstract]   [Full Text] [Related]  

  • 14. Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors.
    Lai IR; Hu RH; Chang KJ
    Hepatogastroenterology; 2005; 52(63):826-8. PubMed ID: 15966213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A ruptured recurrent small bowel gastrointestinal stromal tumour causing hemoperitoneum.
    Lai EC; Chung KM; Lau SH; Lau WY
    Front Med; 2015 Mar; 9(1):108-11. PubMed ID: 25001102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
    Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
    Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Curative resection for bulky gastrointestinal stromal tumor with conversion therapy by imatinib].
    Nishimura T; Sakata K; Maeda Y; Nagashima Y; Okada T; Nakamura M; Setoguchi M
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2202-4. PubMed ID: 22202330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report.
    Bongiovanni A; Ricci M; Riva N; Calpona S; Oboldi D; Pieri F; Cavaliere D; Mercatali L; Liverani C; La Manna F; De Vita A; Foca F; Gunelli E; Amadori D; Ibrahim T
    Future Oncol; 2014 Dec; 10(15):2423-7. PubMed ID: 25525851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electronic clinical challenges and images in GI. Cystic GIST of the lesser omentum.
    Ouazzani A; Lefebvre JC; Mefire Y; Guérin E; Dryjski J; Vaneukem P
    Gastroenterology; 2008 Jun; 134(7):e1-2. PubMed ID: 18485902
    [No Abstract]   [Full Text] [Related]  

  • 20. [A case of recurrent gastrointestinal stromal tumor with complete response from treatment with reduced dose of imatinib mesylate].
    Toyokawa T; Yamashita Y; Yamamoto A; Shimizu S; Inoue T; Ikehara T; Sakashita K; Kanehara I; Teraoka H; Nishiguchi Y
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1723-5. PubMed ID: 23152028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.